| | | Survey I n = 415 | Survey II n = 427 | Survey III n = 421 | Survey IV n = 456 | Survey V n = 274 | for trend |
| | Age, years, mean (SD) | 57.9 (8.3) | 58.6 (8.1) | 59.9 (7.5) | 61.1 (6.9) | 62.6 (6.9) | <0.001 | | Sex | | Men, n (%) | 303 (73.0) | 298 (69.8) | 300 (71.3) | 309 (67.8) | 204 (74.5) | 0.79 | | Women, n (%) | 112 (27.0) | 129 (30.2) | 121 (28.7) | 147 (32.2) | 70 (25.5) | | Duration of education, years, mean (SD) | 11.4 (3.6) | 11.6 (3.5) | 11.9 (3.3) | 12.1 (3.1) | 13.0 (3.1) | <0.001 | | Employed, n (%) | 71 (17.1) | 75 (17.6) | 154 (36.6) | 122 (26.9) | 121 (44.2) | <0.001 | | Index event | | Myocardial infarction, n (%) | 114 (27.5) | 115 (26.9) | 98 (23.2) | 154 (33.8) | 95 (34.7) | 0.007 | | Unstable angina, n (%) | 94 (22.7) | 95 (22.3) | 112 (26.6) | 142 (31.1) | 47 (17.2) | 0.56 | | PCI, n (%) | 99 (23.9) | 101 (23.7) | 134 (31.8) | 113 (24.8) | 116 (42.3) | 0.001 | | CABG, n (%) | 108 (26.0) | 116 (27.2) | 77 (18.3) | 47 (10.3) | 16 (5.8) | <0.001 | | Body mass index, mean (SD) | 27.5 (3.7) | 28.1 (4.1) | 28.6 (4.3) | 28.9 (4.4) | 29.2 (4.4) | <0.001 | | Diabetes, n (%) | 62 (14.9) | 71 (16.6) | 128 (30.4) | 152 (30.3) | 103 (37.6) | <0.001 | | β-Blockers, % | 245 (59.0) | 273 (63.9) | 366 (87.4) | 368 (80.7) | 254 (92.7) | <0.001 | | ACE inhibitors/sartans, % | 190 (45.8) | 203 (47.5) | 330 (78.8) | 351 (77.0) | 244 (89.1) | <0.001 | | ACE inhibitors, % | 190 (45.8) | 203 (47.5) | 312 (74.5) | 302 (66.2) | 205 (74.8) | <0.001 | | Sartans, % | 0 (0.0) | 0 (0.0) | 22 (5.3) | 52 (12.5) | 39 (14.2) | <0.001 | | Calcium antagonists, % | 119 (28.7) | 142 (33.3) | 88 (21.0) | 94 (20.6) | 76 (27.7) | 0.01 | | Diuretics, % | 71 (17.1) | 86 (21.1) | 134 (32.1) | 163 (35.8) | 113 (41.2) | <0.001 | | Other, % | 2 (0.5) | 9 (2.1) | 10 (2.4) | 31 (6.8) | 8 (2.9) | <0.001 | | Number of blood pressure lowering drugs, mean (SD) | 1.51 (0.92) | 1.67 (1.00) | 2.22 (0.89) | 2.23 (1.04) | 2.54 (0.83) | <0.001 |
|
|
